BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) announced today that a team of European scientists reported that in a group of 171 previously-treated multiple myeloma patients (cancer of the bone marrow), the patient group whose cancer cells had the highest levels of Tß4 had a greater chance of not having recurrences of the disease and longer overall survival than a group of patients in the study with the lowest levels of Tß4.
